223 related articles for article (PubMed ID: 26415559)
21. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
22. Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era.
Hong S; Rybicki L; Corrigan D; Hamilton BK; Sobecks R; Kalaycio M; Gerds AT; Dean RM; Hill BT; Pohlman B; Jagadeesh D; Anwer F; Majhail NS
Hematol Oncol Stem Cell Ther; 2021 Dec; 14(4):318-326. PubMed ID: 33301747
[TBL] [Abstract][Full Text] [Related]
23. [Results of unrelated umbilical cord blood stem cell transplantation for 65 patients in China].
Liao C; Yang X; Xu ZP; Huang YN; Wu SQ; Chen JS; Li Y; Tang XW; Wu JY
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):220-3. PubMed ID: 16624064
[TBL] [Abstract][Full Text] [Related]
24. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.
Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057
[TBL] [Abstract][Full Text] [Related]
25. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.
Konuma T; Tsukada N; Kanda J; Uchida N; Ohno Y; Miyakoshi S; Kanamori H; Hidaka M; Sakura T; Onizuka M; Kobayashi N; Sawa M; Eto T; Matsuhashi Y; Kato K; Ichinohe T; Atsuta Y; Miyamura K;
Am J Hematol; 2016 May; 91(5):E284-92. PubMed ID: 26910296
[TBL] [Abstract][Full Text] [Related]
26. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
[TBL] [Abstract][Full Text] [Related]
27. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.
Robin M; Sanz GF; Ionescu I; Rio B; Sirvent A; Renaud M; Carreras E; Milpied N; Mohty M; Beguin Y; Bordigoni P; de Witte T; Picardi A; Purtill D; Gluckman E; Kroger N; Rocha V
Leukemia; 2011 Jan; 25(1):75-81. PubMed ID: 20882048
[TBL] [Abstract][Full Text] [Related]
28. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
29. Has umbilical cord blood transplantation for AML become mainstream?
Ballen KK; Barker JN
Curr Opin Hematol; 2013 Mar; 20(2):144-9. PubMed ID: 23314845
[TBL] [Abstract][Full Text] [Related]
30. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
31. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
32. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
33. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.
Rio B; Chevret S; Vigouroux S; Chevallier P; Fürst S; Sirvent A; Bay JO; Socié G; Ceballos P; Huynh A; Cornillon J; Françoise S; Legrand F; Yakoub-Agha I; Michel G; Maillard N; Margueritte G; Maury S; Uzunov M; Bulabois CE; Michallet M; Clement L; Dauriac C; Bilger K; Gluckman E; Ruggeri A; Buzyn A; Nguyen S; Simon T; Milpied N; Rocha V;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):445-53. PubMed ID: 25460357
[TBL] [Abstract][Full Text] [Related]
34. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.
Peffault de Latour R; Brunstein CG; Porcher R; Chevallier P; Robin M; Warlick E; Xhaard A; Ustun C; Larghero J; Dhedin N; Mohty M; Socié G; Weisdorf D
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1355-60. PubMed ID: 23791622
[TBL] [Abstract][Full Text] [Related]
35. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis.
Chen YH; Xu LP; Liu DH; Chen H; Zhang XH; Han W; Wang FR; Wang JZ; Wang Y; Huang XJ; Liu KY
Chin Med J (Engl); 2013 Jul; 126(13):2499-503. PubMed ID: 23823825
[TBL] [Abstract][Full Text] [Related]
36. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
37. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
38. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?
Ruggeri A; Ciceri F; Gluckman E; Labopin M; Rocha V;
Best Pract Res Clin Haematol; 2010 Jun; 23(2):207-16. PubMed ID: 20837332
[TBL] [Abstract][Full Text] [Related]
39. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
Hahn T; McCarthy PL; Hassebroek A; Bredeson C; Gajewski JL; Hale GA; Isola LM; Lazarus HM; Lee SJ; Lemaistre CF; Loberiza F; Maziarz RT; Rizzo JD; Joffe S; Parsons S; Majhail NS
J Clin Oncol; 2013 Jul; 31(19):2437-49. PubMed ID: 23715573
[TBL] [Abstract][Full Text] [Related]
40. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older.
Bashey ZA; Zhang X; Brown S; Jackson K; Morris LE; Holland HK; Bashey A; Solomon SR; Solh M
Bone Marrow Transplant; 2018 Jun; 53(6):756-763. PubMed ID: 29523888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]